Format

Send to

Choose Destination
PLoS One. 2011;6(10):e26250. doi: 10.1371/journal.pone.0026250. Epub 2011 Oct 13.

Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer.

Author information

1
Department of Pathology, New York University School of Medicine, New York, New York, United States of America.

Erratum in

  • PLoS One. 2011;6(10); doi:10.1371/annotation/fe4fca93-8211-430e-bfe0-8a371b9cc20d.

Abstract

Hormones, including estrogen and progesterone, and their receptors play an important role in the development and progression of ovarian carcinoma. Androgen, its receptor and coactivators have also been implicated in these processes. p44/Mep50/WDR77 was identified as a subunit of the methylosome complex and lately characterized as a steroid receptor coactivator that enhances androgen receptor as well as estrogen receptor-mediated transcriptional activity in a ligand-dependent manner. We previously described distinct expression and function of p44 in prostate, testis, and breast cancers. In this report, we examined the expression and function of p44 in ovarian cancer. In contrast to findings in prostate and testicular cancer and similar to breast cancer, p44 shows strong cytoplasmic localization in morphologically normal ovarian surface and fallopian tube epithelia, while nuclear p44 is observed in invasive ovarian carcinoma. We observed that p44 can serve as a coactivator of both androgen receptor (AR) and estrogen receptor (ER) in ovarian cells. Further, overexpression of nuclear-localized p44 stimulates proliferation and invasion in ovarian cancer cells in the presence of estrogen or androgen. These findings strongly suggest that p44 plays a role in mediating the effects of hormones during ovarian tumorigenesis.

PMID:
22022581
PMCID:
PMC3192795
DOI:
10.1371/journal.pone.0026250
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center